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For more than 30 years, the production of research antibodies has been dominated by hybridoma
technologies, while modern recombinant technologies have lagged behind. Here I discuss why this
situation must change if we are to generate reliable, comprehensive reagent sets on a genome-wide
scale, and I describe how a cultural shift in the research community could revolutionize and mod-
ernize the afﬁnity reagent ﬁeld. In turn, such a revolution would pay huge dividends by closing the
gap between basic research and therapeutic development, thus enabling the development of myriad
new therapies for unmet medical needs.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.In most respects, the human genome project has been a
resounding success. As a direct result of the initiative, not only do
we have access to the complete human genome, as importantly,
sequencing technologies have advanced to the point where whole
genome sequencing has become a daily affair. Moreover, the
astounding advances in DNA sequencing technology have dove-
tailed with, and often driven, the development of numerous other
technologies for the systematic analysis of genomes, transcripto-
mes and proteomes. Consequently these are best of times for life
scientists engaged in basic research. Our basic knowledge of the cell
far exceeds what we imagined even a decade ago, and we have the
tools to expand this knowledge almost inﬁnitely within the spheres
of established technologies.
However, a fundamental tenet of the human genome project
was that a complete view of the genome would open up myriad
new avenues for therapy. Unfortunately, in this crucial aspect,
the promise of the genomics era has not been fulﬁlled. More than
a decade after completion of the genome, the drug development
industry has not beneﬁtted greatly from the explosion of basic
knowledge, and in fact, the development of novel therapies has
declined over this period. Thus, these are the worst of times for
researchers engaged in drug discovery. The beneﬁts of genomics
and systems biology have not penetrated to the level of drug devel-
opment and there is no obvious path forward for integrating thisal Societies. Published by Elsevierwealth of basic knowledge into the practical demands of drug
development.
Here, I focus on one problem that has contributed to the vast di-
vide between the promise of genomics and the reality of drug
development: the wide gap between the advanced tools for the
manipulation of nucleic acids and the relatively primitive tools
for manipulation of proteins. Proteins are central to the control
of virtually all cellular processes, and virtually all drugs act by
modulating the activities of proteins. Thus, it is reasonable to pro-
pose that the translation of genomic knowledge to therapeutic
development will require a toolkit that enables the manipulation
of proteins with the same speed and precision that is common-
place for the manipulation of DNA and RNA. Ideally, this toolkit
would be comprehensive, providing us with tools that could track,
localize, and modulate any protein in the cell. Such a toolkit would
revolutionize our understanding of normal and diseased cellular
states, andmoreover, these tools could be converted into therapeu-
tics that would act to inhibit or activate proteins in a selective
manner to reverse the aberrant protein functions associated with
disease.
Given the urgent need for such tools, it is disappointing to
contemplate the state of the technology on which our supply of
protein afﬁnity reagents depends. The vast majority of afﬁnity re-
agents are monoclonal antibodies that are still raised using hybrid-
oma technology that has changed little since it was invented more
than thirty years ago [1]. The method relies on animal immuniza-
tion followed by immortalization of individual antibody-producingB.V. Open access under CC BY-NC-ND license. 
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antibodies.
Although traditional monoclonal antibodies are used through-
out biological research, the hybridoma technology suffers from
fundamental drawbacks that have limited afﬁnity reagents from
reaching their full potential. First, the process occurs in the uncon-
trolled serum environment and there is no control over the selec-
tion process, which may be suitable for stable antigens, but not for
sensitive antigens. In addition, there is no control over which epi-
topes are targeted, and thus, no guarantee that immunodominant
epitopes will be those that are of interest to researchers. Second,
the approach provides antibody proteins but not the encoding
DNA, and it is not possible to alter or improve the antibody without
complicated procedures that convert the molecule to a recombi-
nant form. Third, hybridoma methods involve the use of animals
and cumbersome procedures that are inherently unsuited for
adaptation to a high-throughput pipeline. Large animal facilities
must be maintained to supply the current demands of research
groups and the facilities are not scalable without tremendous cost
in infrastructure and maintenance. Fourth, natural repertoires are
restricted to eliminate antibodies against self, and this makes it dif-
ﬁcult to raise effective antibodies against epitopes that are highly
conserved across species. The limits of hybridoma technology are
particularly acute in the post-genomics era, as the methodology
is inherently low throughput and not suited to targeting the tens
of thousands of proteins revealed by whole-genome sequencing.
As an alternative to hybridoma technologies, the last decade has
seen the emergence of robust molecular display technologies that
provide completely controlled approaches to the generation of
antibodies and other afﬁnity reagents [2–4]. In phage display, the
most popular display technology, libraries of antibody fragments
are displayed on phage particles that also encapsulate the encoding
DNA [5,6]. Phage pools containing billions of unique antibodies can
be used in selections to isolate antibodies that recognize antigens
of interest, and the sequence of each antibody can be decoded by
sequencing of the linked DNA. In addition, the selections are per-
formed under controlled, in vitro conditions that can be tailored
to suit the demands of the antigen.
The combination of display technologies with structure-based
design has enabled the development of ‘‘synthetic’’ antibody li-
braries with man-made antigen-binding sites and libraries built
with alternative, non-antibody scaffolds [7,8]. Synthetic reper-
toires circumvent the need for natural antibodies altogether and
possess advantages due to their highly deﬁned nature. Scaffolds
can be chosen for high stability and expression, can be modiﬁed
to suit the demands of particular applications, and can be designed
for facile afﬁnity maturation. Unlike natural repertoires, synthetic
repertoires are completely naïve and are not biased against self-
antigens. These features of phage-displayed synthetic antibody
libraries obviate many of the limitations of hybridoma technology,
and the system is much more suited to high-throughput applica-
tions, since the entire process relies on simple molecular biology
techniques.
Not only can recombinant antibody libraries more effectively
ﬁll all the applications of hybridoma antibodies, they can also ex-
pand the reach of afﬁnity reagents to entirely new areas. For ther-
apeutics, high stability and low immunogenicity are essential, and
synthetic antibodies libraries can be designed to directly supply
molecules with these characteristics. Also, natural antibodies do
not function intracellularly but it is possible to produce synthetic
‘‘intrabodies’’ or alternative scaffolds that are adapted for folding
and function inside cells [8]. Recombinant antibodies are also mod-
ular, because they can be fused genetically to additional domains
to endow additional functions, such as ﬂuorescence to track pro-
tein localization and trafﬁcking. Finally, while hybridoma methodshave changed little over time, recombinant methods continue to
evolve and improve, and almost certainly, new applications for re-
combinant antibodies will arise as the technologies evolve.
Despite the power of recombinant antibody libraries, hybrid-
oma methods still dominate the ﬁeld for a number of reasons.
The early development of hybridomamethods provided the advan-
tage of familiarity, and for most antibody users, conservatism
trumps innovation. In contrast, dissemination of in vitro display
technologies was hampered by restrictive intellectual property
rights, but most platform patents have either expired or will do
so over the next few years. Also, most in vitro technology develop-
ment efforts have focused on developing more powerful, special-
ized methods for selections rather than developing simpler,
standardized methods that could expand the reach of the technol-
ogy. As a consequence of these conditions, the research community
still has only a vague awareness of the advantages of in vitro
antibody technology relative to the more familiar hybridoma
technology.
However, the times are changing, and it is becoming clear that
complacent reliance on hybridoma methods will not sufﬁce if
afﬁnity reagents are to keep pace with advances in genomics. Rad-
ical improvements in afﬁnity reagent technologies will be abso-
lutely necessary if we hope to exploit genomic knowledge for
therapeutic breakthroughs. Only in vitro methods have the fea-
tures that will be required to adapt afﬁnity reagent generation to
the kinds of high-throughput pipelines that are commonplace in
genomics research and other areas of systems biology.
In particular, I believe that the emerging ﬁeld of high-through-
put afﬁnity reagent development is perfectly poised to mesh with
the well-established ﬁeld of protein interactome mapping. The
common thread is the understanding that most large proteins
can be broken down into smaller domains that can be produced
and studied individually. This realization has already enabled the
comprehensive analysis of interactomes for many structural do-
main families. These domains could also be ideal antigens for
in vitro high-throughput pipelines for the generation of recombi-
nant antibodies on a genome-wide scale [9]. A pilot study of the
SH2 domain family has already proven that protein domains can
be used as antigens with remarkable success [10]. By combining
domain antigens with synthetic antibody libraries, it should be
possible to target the proteome with a comprehensive set of re-
combinant afﬁnity reagents that would enable the rapid elucida-
tion of protein function. Most importantly, these afﬁnity reagents
would also enable the identiﬁcation of key protein–protein interac-
tions that are involved in disease states, thus providing critical
links between our vast stores of genomic data and the urgent need
for new therapeutics.
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